CRISPR Therapeutics Shifts from Ex Vivo to In Vivo and RNA Platform with CTX310 De-Risking Amid CASGEVY Disappointment and Takeover Rumors

CRISPR Therapeutics' stock narrative is shifting from a single-product ex vivo story to a broader in vivo and RNA platform story. Its first product, CASGEVY, an ex vivo gene therapy, disappointed. The company's focus on CTX310 de-risks its pipeline, while takeover rumors fuel speculation. CRISPR's diversified approach positions it for future success in gene therapy.